文献速递淋巴瘤

177Lu-lilotomab satetraxetan治疗复发/难治性惰性非霍奇金淋巴瘤的1/2a期研究

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2020-01-01

这项1/2a期研究在74例复发/难治性惰性非霍奇金B细胞淋巴瘤患者(含57例滤泡性淋巴瘤)中评估单剂CD37靶向放射免疫治疗药物177Lu-lilotomab satetraxetan,给药前使用利妥昔单抗和冷抗体lilotomab。单次给药总缓解率61%(滤泡性淋巴瘤65%),完全缓解30%;最常见不良事件为可逆性3/4级中性粒细胞减少(31.6%)和血小板减少(26.3%)。

要点

  • 单次给药总缓解率61%,滤泡性淋巴瘤65%,完全缓解30%。
  • ≥2线治疗滤泡性淋巴瘤(n=37)总缓解率70%,完全缓解32%。
  • 利妥昔单抗难治且≥2线治疗滤泡性淋巴瘤(n=21)总缓解率67%,完全缓解24%。

核心结论

  • 177Lu-lilotomab satetraxetan可能为复发/难治性非霍奇金淋巴瘤提供有价值的替代治疗选择,尤其适用于不适合更强治疗方案的合并症患者。

研究设计与样本

  • 1/2a期研究,纳入74例复发/难治性惰性非霍奇金B细胞淋巴瘤患者,其中57例为滤泡性淋巴瘤。
  • 177Lu-lilotomab satetraxetan为单剂CD37靶向放射免疫治疗,给药前使用利妥昔单抗和冷抗CD37抗体lilotomab。
  • 试验注册号NCT01796171。

主要发现

  • 最常见不良事件为可逆性3/4级中性粒细胞减少(31.6%)和血小板减少(26.3%),中性粒细胞和血小板计数最低点出现在放射免疫治疗后5至7周。
  • 最常见的非血液学不良事件为1/2级恶心(15.8%)。
  • 单次给药总缓解率为61%(滤泡性淋巴瘤患者为65%),其中完全缓解占30%。
  • ≥2线治疗的滤泡性淋巴瘤患者(n=37)总缓解率为70%,完全缓解率为32%。
  • 利妥昔单抗难治且≥2线治疗的滤泡性淋巴瘤患者(n=21)总缓解率为67%,完全缓解率为24%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the "cold" anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with ≥2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL ≥2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kolstad A, Illidge T, Bolstad N, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020. PMID: 32877524. doi:10.1182/bloodadvances.2020002583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。